NCT01330277 (BioHunter) is a clinical trial in Hunter Syndrome, sponsored by CENTOGENE GmbH Rostock.

Who is sponsoring NCT01330277?

NCT01330277 is sponsored by CENTOGENE GmbH Rostock.

What condition does NCT01330277 study?

NCT01330277 studies Hunter Syndrome, Mucopolysaccharidosis II, Hunter's Syndrome, Mild Form, Hunter's Canal Syndrome.

Is NCT01330277 still recruiting?

NCT01330277 is currently terminated. Last updated 10 February 2023.

Last reviewed 2023-02-10 · How we verify

NCT01330277: BioHunter

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarkers for Hunter Syndrome

Terminated Last updated 10 February 2023

What this trial tests

trial in Hunter Syndrome in 11 participants. Terminated before completion.

Timeline

20 August 2018

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	CENTOGENE GmbH Rostock
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	11
Start date	20 August 2018
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	4 locations across Mexico

Conditions studied

Hunter Syndrome — all drugs for Hunter Syndrome →
Mucopolysaccharidosis II — all drugs for Mucopolysaccharidosis II →
Hunter's Syndrome, Mild Form — all drugs for Hunter's Syndrome, Mild Form →
Hunter's Canal Syndrome — all drugs for Hunter's Canal Syndrome →

Sponsor

CENTOGENE GmbH Rostock

Who can join

Adults 2 Months to 50, male only, with Hunter Syndrome or Mucopolysaccharidosis II. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

International, multicenter, observational, longitudinal study to establish Hunter Syndrom biomarker/s and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hunter Syndrome

Currently open trials in the same condition.

NCT06031259 — Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairme · Phase 2, PHASE3 · active not recruiting
NCT02171104 — MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis · Phase 2 · active not recruiting

Other CENTOGENE GmbH Rostock trials

Trials by the same sponsor.

NCT06040008 — Investigating the Impact of Environmental Factors on the Transcriptomics Profile in Healthy Individuals · completed
NCT05075187 — Epidemiological Study in FRONtoTemporal Dementia · completed
NCT04925804 — Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) · completed
NCT04548921 — Biomarker for Friedreich's Ataxia (BioFridA) · unknown
NCT03866590 — Pyruvate Kinase Deficiency Epidemiological Study (PIECE) · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01330277 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CENTOGENE GmbH Rostock
Last refreshed: 10 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01330277.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing